Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
114 hedge funds and large institutions have $2.08B invested in Centessa Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 36 increasing their positions, 36 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 6 → 12 (+6)
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
20% more capital invested
Capital invested by funds: $1.74B → $2.08B (+$346M)
11% more funds holding
Funds holding: 103 → 114 (+11)
9.91% more ownership
Funds ownership: 84.45% → 94.36% (+9.9%)
0% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 36
97% less call options, than puts
Call options by funds: $117K | Put options by funds: $3.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$59.9M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$17.6M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.3M |
| 4 |
CC
Commodore Capital
New York
|
+$14.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$51.5M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$16M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$10.2M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.34M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$8.38M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GSEP
126
Golden State Equity Partners
South Coast Metro,
California
| – | -$27.2K | -1,700 | Closed |
|
|
BTI
127
Blue Trust Inc
Alpharetta,
Georgia
| – | -$9.16K | -1,015 | Closed |
|
|
NS
128
NBC Securities
Birmingham,
Alabama
| – | -$2K | -138 | Closed |
|
129
Simplex Trading
Chicago,
Illinois
| – | -$1K | -108 | Closed |
|
CNTA Hedge Fund Activity: Q4 2024 in Review
114 of the 7,597 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q4 2024, worth a combined $2.08B — up 20% from $1.74B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CNTA positions and 15 closed out — a net gain of 11 holders — while 36 added to existing stakes and 36 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $59.9M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $51.5M sold.
- 114 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q4 2024, up from 103 in Q3 2024.
- Funds reported $2.08B of Centessa Pharmaceuticals stock for Q4 2024, up 20% quarter-over-quarter.
- 26 funds opened new Centessa Pharmaceuticals positions in Q4 2024 and 15 closed out, a net change of +11 holders.
- The largest Centessa Pharmaceuticals buyer in Q4 2024 was Janus Henderson Group, an estimated $59.9M added.
- The largest Centessa Pharmaceuticals seller in Q4 2024 was EcoR1 Capital, an estimated $51.5M sold.
Based on aggregated 13F filings for Q4 2024.